The racial disparity in outcomes in endometrial cancer: Could this be explained on a molecular level?

Gynecologic Oncology

Volumn 102, Issue 3, 2006, Pages 440-446

  Schimp, V L ^a   Ali Fehmi, R ^a   Solomon, L A ^a   Hammoud, A ^a   Pansare, V ^a   Morris, R T ^a   Munkarah, A R ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Endometrial carcinoma; Ethnicity; HIF 1 ; Ki 67; Molecular profile; p53; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P53; VASCULOTROPIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; ENDOMETRIUM CANCER; ETHNIC DIFFERENCE; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RACE DIFFERENCE; STATISTICAL ANALYSIS; TISSUE MICROARRAY;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646431196     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.041     Document Type: Article

References (40)

1. Edwards B.K., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 97 19 (2005) 1407-1427
2. Hicks M., Phillips J.L., et al. The national cancer data base report on endometrial carcinoma in African-American women. Cancer 83 12 (1998) 2629-2637
3. Aziz H., Rotman M., et al. Poor survival of black patients in carcinoma of the endometrium. Int. J. Radiat. Oncol. Biol. Phys. 27 2 (1993) 293-301
4. Barrett R.J., Harlan L.C., Wesley M.N., Hill H.A., Chen V.W., Clayton L.A., et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am. J. Obstet. Gynecol. 173 (1995) 414-423
5. Mark E., and Sherman S.S.D. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98 1 (2003) 176-186
6. Hill H., Coates R.J., Austin H., Correa P., Robboy S.J., Chen V., et al. Racial differences in tumor grade among women with endometrial cancer. Gynecol. Oncol. 56 (1995) 154-163
7. Coates R.J., Click L.A., Harlan L.C., Robboy S., Barrett R.J., Eley J.W., et al. Differences between black and white patients with cancer of the uterine corpus in interval from symptom recognition to initial medical consultation (United States). Cancer Causes Control 7 (1996) 328-336
8. Connell P.P., et al. Race and clinical outcome in endometrial carcinoma. Obstet. Gynecol. 94 5 (1999) 713-720
9. Randall T.C., and Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. J. Clin. Oncol. 21 22 (2003) 4200-4206
10. Liu R., Conaway M., Rodriguez G.C., Soper J.T., Clarke-Pearson D.L., and Berchuck A. Relationship between race and interval to treatment in endometrial cancer. Obstet. Gynecol. 86 4 (1995) 486-490
11. Hill H., Eley W.J., Harlan L.C., Greenberg R.S., Barrett II R.J., and Chen V. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet. Gynecol. 88 6 (1996) 919-926
12. Schottenfeld D. Determinants of black/white survival differences among women with endometrial cancer. Gynecol. Oncol. 56 2 (1995) 151-153
13. Zheng W., Cao P., Zheng M., Kramer E.E., and Godwin T.A. p53 Overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol. Oncol. 61 (1996) 167-174
14. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., Koukourakis M.I., and Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1 alpha and 2 alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 5 (2002) 1055-1063
15. Hamel N., Sebo T.J., Wilson T.O., Keeney G.L., Roche P.C., Suman V.J., et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol. Onol. 62 (1996) 192-198
16. Fujisawa T., Watanabe J., Kamata Y., Hamano M., Hata H., and Kuramoto H. VEGF expression and its regulation by p53 gene transfection in endometrial carcinoma cells. Hum. Cell 16 1 (2002) 47-53
17. Oreskovic S., et al. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol. Oncol. 93 1 (2004) 34-40
18. Ronnett B.M., Zaino R.J., Ellenson L.H., and Kurman R.J. Endometrial carcinoma. In: K. RJ (Ed). Blaustein's Pathology of the Female Genital Tract (2002), Springer, New York 501-560
19. Mariani A., Sebo T.J., Katzmann J.A., Keeney G.L., Roche P.C., et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am. J. Obstet. Gynecol. 182 (2000) 1535-1544
20. Rouba Ali-Fehmi M.C., Khalifeh I., Malone J.M., Morris R., Lawrence W.D., and Munkarah A.R. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98 7 (2003) 1423-1429
21. Birner P., et al. Overexpression of hypoxia-inducible factor 1{{alpha}} is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60 17 (2000) 4693-4696
22. Stefansson I.M., Salvesen H.B., Immervoll H., and Akslen L.A. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 44 (2004) 472-479
23. Ferrandina G., Ranelletti F.O., Gallotta V., Martinelli E., Zannoni G.F., et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol. Oncol. 98 3 (2005) 383-389
24. Mariani A., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detec. Prev. 27 6 (2003) 434-441
25. Zhong H., et al. Overexpression of hypoxia-inducible factor 1{{alpha}} in common human cancers and their metastases. Cancer Res. 59 22 (1999) 5830-5835
26. Theodoropoulos V.E., et al. Hypoxia-inducible factor 1[alpha] expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46 2 (2004) 200-208
27. Pansare V.M., Ionescu M.C., Halloush R., Hammoud A., Munkarah A.R., et al. Increased expression of hypoxia-inducible factor 1a in type II endometrial carcinomas. Mod. Path. 17 1 (2004) 210
28. Society A.C. Cancer Facts and Figures. 2004 [cited].
29. Matthews R.P., et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol. Oncol. 65 2 (1997) 206-212
30. Plaxe S.C., and Saltzstein S.L. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol. Oncol. 65 1 (1997) 8-12
31. Maxwell G.L., et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin. Cancer Res. 6 8 (2000) 2999-3005
32. Jeon Y.-T., et al. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol., Biomarkers Prev. 13 9 (2004) 1538-1542
33. Dupont J., et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol. Oncol. 94 2 (2004) 449
34. Mariani A., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detec. Prev. 27 6 (2003) 434
35. Giatromanolaki A., Sivridis E., Brekken R., Thorpe P.E., Anastasiadis P., Gatter K.C., et al. The angiogenic "Vascular Endothelial Growth Factor/flk-1 (KDR) Receptor" pathway in patients with endometrial carcinoma. Cancer 92 10 (2001) 2569-2577
36. Yokoyama Y., et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF Receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 9 4 (2003) 1361-1369
37. Sivridis E., Giatromanolaki A., Anastasiadis P., Georgiou L., Gatter K.C., et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J. Pathol. 196 4 (2002) 416-422
38. Hirai M., et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol. Oncol. 80 2 (2001) 181
39. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., Spiliadi C., Theodoropoulus G.E., Tsoukala V., et al. Evaluation of hypoxia-inducible factor 1a overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 95 (2005) 425-431
40. Koukourakis M.I., et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61 5 (2001) 1830-1832